ICH Guidelines for Pharmacovigilance.pdf

The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.

1. ICH Guidelines for
Pharmacovigilance
Ensuring Drug Safety and Efficacy
SUBMITTED BY:
NEHA GUPTA
B.PHARM 4th year
2010640500040
SUBMITTED TO:
Mr. SAQUIB TANVEER
FACULTY OF PHARMACY

2. Introduction

3. •Pharmacovigilance is the science and activities focused on detecting, assessing,
understanding, and preventing adverse effects or any other drug-related problems. This
involves monitoring the effects of medicinal products after they have been released on
the market to ensure that any new and unforeseen risks are identified and managed
appropriately.
What is Pharmacovigilance?

4. •Early Detection of Adverse Reactions: Pharmacovigilance systems are designed to
identify potential adverse reactions as early as possible. This helps prevent harm to
patients by taking timely actions, such as updating safety information or withdrawing
unsafe products.
•Continuous Monitoring: Even after a drug is approved, its safety is continuously monitored
to detect any rare or long-term adverse effects that might not have been evident during
clinical trials.
Importance: Patient Safety

5. •Ensuring Effectiveness: By monitoring drugs in the real world, pharmacovigilance helps ensure
that medications work as intended across diverse populations and settings.
•Improving Therapeutic Outcomes: By managing and mitigating risks associated with drug use,
pharmacovigilance contributes to better therapeutic outcomes for patients.
Regulatory Compliance
•
•Meeting Legal Requirements: Pharmaceutical companies and healthcare providers must
comply with legal and regulatory requirements for monitoring and reporting drug safety.
Pharmacovigilance ensures adherence to these regulations.
•Informed Decision-Making: It provides critical safety data that supports regulatory authorities
in making informed decisions regarding drug approvals, withdrawals, and labeling changes.
Efficacy of Medications

6. Organization and Objectives of ICH

7. •Founded in 1990: The ICH was established in 1990 to bring together regulatory authorities
and the pharmaceutical industry to discuss and develop harmonized technical guidelines
and standards for drug development and registration.
•Collaboration:The ICH involves collaboration among regulatory bodies (like the FDA in the
US, EMA in Europe, and PMDA in Japan) and pharmaceutical industry associations. This
cooperation aims to streamline and harmonize the drug approval process across different
regions.
International Council for Harmonisation (ICH)

8. •Harmonize Technical and Scientific Requirements: The primary goal of ICH is to create
common guidelines that harmonize the technical and scientific aspects of drug development.
This includes standards for clinical trials, safety reporting, and product quality. By harmonizing
these requirements, the ICH helps to reduce discrepancies between different countries'
regulations.
•Ensure Safety, Efficacy, and Quality of Medicines: ICH guidelines ensure that medicinal
products meet high standards of safety, efficacy, and quality before they reach the market. This
is achieved through comprehensive and standardized testing and evaluation processes.
•Minimize Duplication in Drug Development and Registration: Harmonization helps to reduce
the need for repetitive testing and documentation when seeking drug approval in multiple
regions. This minimizes the duplication of efforts and resources, making the drug development
process more efficient and cost-effective. It also speeds up the availability of new medicines to
patients worldwide.
Objectives

9. Expedited Reporting

10. •Expedited Reporting: Expedited reporting involves promptly notifying regulatory
authorities about serious and unexpected adverse drug reactions (ADRs). This rapid
reporting is crucial for ensuring patient safety by allowing for quick action, such as issuing
warnings or modifying drug usage guidelines.
•Unexpected Adverse Events: These are adverse reactions that are not consistent with the
current product information or labeling. If an ADR occurs that is not listed in the product's
approved documentation, it is considered unexpected and must be reported promptly.
Definition

11. •Serious Adverse Events (SAEs):
•Death: If the adverse reaction results in the death of a patient.
•Life-Threatening: If the patient is at immediate risk of death from the adverse reaction.
•Hospitalization: If the adverse reaction requires or prolongs hospitalization.
•Disability: If the adverse reaction results in a significant, persistent, or permanent
disability or incapacity.
Criteria for Expedited Reporting

12. •15 Calendar Days: Regulatory guidelines typically require that serious and unexpected
ADRs be reported within 15 calendar days of the sponsor (e.g., pharmaceutical company)
becoming aware of the event. This timeframe ensures that potential risks are
communicated to regulatory authorities swiftly, enabling them to take necessary
measures to protect public health.
Timelines

13. Individual Case Safety Reports
(ICSRs)

14. •ICSRs are used to gather detailed information on adverse events experienced by individual patients.
This data is crucial for identifying potential safety issues with medicinal products, understanding the
nature and frequency of adverse events, and taking appropriate regulatory actions to mitigate risks.
•
Components: Patient Information
•
•Demographics: Information such as age, sex, weight, and ethnicity, which helps in understanding the
context of the adverse event.
•Medical History: Relevant medical background of the patient, including pre-existing conditions and
concurrent medications, which can influence the interpretation of the adverse event.
Purpose:Collect and Analyze Individual Adverse Event
Report

15. •Dosage: The amount of the drug administered, which helps in correlating the dose with the
adverse event.
•Administration: Details on how the drug was administered (e.g., orally, intravenously).
•Batch Number: Specific identification of the drug batch, useful for tracking manufacturing issues.
•
Adverse Event
•Description: A detailed account of the adverse event, including symptoms and circumstances.
•Severity: Classification of the event's seriousness (e.g., mild, moderate, severe).
•Outcome: The result of the adverse event (e.g., recovery, ongoing, fatal).
Drug Information

16. EudraVigilance (EU):
•The system used by the European Medicines Agency (EMA) to manage and analyze
information on suspected adverse reactions to medicines authorized in the European
Economic Area (EEA). It facilitates the early detection of safety signals.
FDA Adverse Event Reporting System (FAERS):
•A database maintained by the US Food and Drug Administration (FDA) for collecting and
analyzing adverse event reports and medication error reports for drugs and therapeutic
biologics. It supports the FDA's post-marketing safety surveillance program.
Reporting Systems

17. Periodic Safety Update Reports (PSURs)

18. Purpose
Regularly Update the Safety Profile of a Drug
PSURs are comprehensive documents that pharmaceutical companies must submit periodically
to regulatory authorities. Their main purpose is to provide an ongoing assessment of the
risk-benefit balance of a medicinal product after it has been marketed. This ensures that any
new safety information is promptly evaluated and acted upon to protect public health.

19. Summary of New Safety Data:
This section includes detailed information on new adverse events, findings from post-marketing
studies, and other relevant safety data collected since the last report. It helps in identifying any
new risks associated with the drug.
Evaluation of Benefit-Risk Balance:
A critical analysis that weighs the drug's benefits against its risks. This evaluation considers the
new safety data in the context of the drug's therapeutic efficacy, ensuring that the overall
benefit-risk profile remains favorable for patients.
Sales and Distribution Data:
Information on the volume of drug sales and distribution patterns. This data helps in
understanding the exposure level of the population to the drug, which is important for assessing
the significance of reported adverse events.
Contents

20. Safety Actions Taken
Details of any actions implemented in response to safety concerns. This can include changes to the
drug’s labeling (e.g., adding warnings or contraindications), updates to the prescribing information, or
even product recalls. These actions are crucial for mitigating risks and ensuring the safe use of the
drug.

21. Typically Every 6 Months, Annually, or as Specified by Regulatory Bodies
The frequency of PSUR submissions depends on the stage of the drug’s lifecycle and regulatory
requirements. Initially, PSURs might be required every 6 months, but this can change to annually
or at intervals specified by regulatory authorities as more safety data becomes available and
the drug’s safety profile stabilizes.
Frequency

22. Harmonized Formats and Tools

23. E2B (R3)
Standard for Electronic Transmission of ICSRs:
E2B (R3) is a standardized format developed by the International Council for Harmonisation (ICH) for the electronic transmission of Individual Case Safety
Reports (ICSRs) between pharmaceutical companies and regulatory authorities. It ensures consistency and efficiency in reporting adverse events, allowing for
seamless communication and data exchange.
E2E
Guidance on Pharmacovigilance Planning and Risk Management:
E2E provides guidance on pharmacovigilance planning and risk management throughout the lifecycle of a medicinal product. It outlines strategies for identifying,
evaluating, and mitigating risks associated with drug use, ensuring continuous monitoring and improvement of the product's safety profile.
MedDRA
Standardized Medical Terminology for Adverse Event Reporting:
MedDRA (Medical Dictionary for Regulatory Activities) is a standardized medical terminology developed by the International Council for Harmonisation (ICH) for
classifying and coding adverse event terms. It provides a common language for reporting adverse events, ensuring consistency and accuracy in data collection,
analysis, and regulatory submissions.

24. Case Studies and Examples

25. Example 1: Case of a Drug Withdrawn from the
Market due to Safety Concerns
Description:
This case study involves a real-life example of a pharmaceutical product that was withdrawn from
the market due to safety concerns. It could include details such as the drug name, the adverse
events or safety issues that led to its withdrawal, and the regulatory actions taken.
Significance:
This example highlights the importance of pharmacovigilance in identifying and addressing safety
issues associated with medicinal products. It underscores the critical role of regulatory authorities
in ensuring the safety of drugs and protecting public health.

26. Description:
This case study showcases a successful example of implementing risk management strategies for a
pharmaceutical product. It could include details of risk assessment methodologies used, risk
mitigation measures implemented, and the impact of these strategies on patient safety.
Significance:
This example demonstrates the effectiveness of proactive risk management approaches in
minimizing the potential risks associated with medicinal products. It emphasizes the importance of
continuous monitoring, evaluation, and adaptation of risk management plans to ensure the safe use
of drugs throughout their lifecycle.
Example 2: Successful Implementation of Risk
Management Strategies

27. Challenges and Future Directions

28. Challenges
Timely ADR Detection and Reporting:
One of the challenges in pharmacovigilance is ensuring timely detection and reporting of adverse
drug reactions (ADRs). Delays in reporting can lead to underestimation of risks and delays in
taking necessary regulatory actions to protect public health.
Data Integration Across Different Systems:
Pharmacovigilance involves the collection and analysis of vast amounts of data from various
sources, including healthcare providers, patients, and regulatory authorities. Integrating these
diverse data sets can be challenging and requires robust systems and processes to ensure data
quality, consistency, and interoperability.

29. Use of Data Analytics and AI in Pharmacovigilance:
The future of pharmacovigilance lies in leveraging advanced technologies such as data analytics
and artificial intelligence (AI) to enhance the detection, assessment, and management of adverse
drug reactions. These technologies can analyze large volumes of data more efficiently, identify
potential safety signals, and facilitate predictive modeling to anticipate safety issues.
Enhanced Global Collaboration and Harmonization:
To address the increasingly global nature of the pharmaceutical industry, there is a need for
enhanced collaboration and harmonization among regulatory authorities, industry stakeholders,
and healthcare providers. By aligning regulatory standards, sharing information, and coordinating
surveillance efforts, global pharmacovigilance can become more effective in ensuring the safety of
medicines worldwide.
Future Directions

30. Conclusion

31. Continuous Improvement in Practices is Vital for
Public Health
•Pharmacovigilance plays a crucial role in safeguarding public health by ensuring the safety
and efficacy of medicinal products. However, achieving this goal requires ongoing efforts to
enhance pharmacovigilance practices.
•Continuous improvement involves implementing new technologies, refining processes, and
fostering collaboration among stakeholders to address emerging challenges and improve
patient outcomes.
•By prioritizing continuous improvement in pharmacovigilance, we can better protect
patients from potential risks associated with medications and promote the safe and
effective use of medicines for the benefit of society as a whole.

32. References

33. Sources
ICH Guidelines and Documents:
The International Council for Harmonisation (ICH) provides guidelines and documents that serve as the basis for harmonizing regulatory requirements for
pharmaceuticals worldwide. These guidelines cover various aspects of drug development, registration, and pharmacovigilance.
Regulatory Authority Websites:
Websites of regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals
and Medical Devices Agency (PMDA) in Japan offer valuable resources and information on pharmacovigilance regulations, guidance documents, and safety
alerts.
Key Pharmacovigilance Literature:
Peer-reviewed journals, books, and publications in the field of pharmacovigilance provide in-depth insights into best practices, methodologies, and emerging
trends in drug safety surveillance and risk management.

34. thankyou

35. Zoho Show
To create beautiful presentations, download Zoho Show from Play Store https://zoho.to/cy7
ICH Guidelines for Pharmacovigilance.pdf
(This PDF has been generated using Zoho Show)